Table 2.
Systemic treatment and surgical characteristics
| All (N = 175) (%) | Left BC Group (N = 84) (%) | Right BC Group (N = 91) (%) | P value | |
|---|---|---|---|---|
| Anthracyclines | ||||
| Cumulative dose- mg/m2 BSA | ||||
| (Median [Q1–Q3]) | 350 (292–499) | 352 (295–497) | 349 (290–499) | 0.799 |
| Taxanes | ||||
| Cumulative dose- mg/m2 BSA | 297 | 297 | 298 | 0.783 |
| (Median [Q1–Q3]) | (276–594) | (281–422) | (273–768) | |
| Cyclophosphamide | ||||
| Cumulative dose- mg/m2 BSA | 2316 | 2344 | 2268 | 0.482 |
| (Median [Q1–Q3]) | (1758–2924) | (1763–2992) | (1758–2829) | |
| CT Scheme | ||||
| AC/EC/FAC/FEC + taxanes | 95 (54.3%) | 40 (47.6%) | 55 (60.4%) | 0.235 |
| AC/EC/FAC/FEC without taxanes | 69 (39.4%) | 38 (45.3%) | 31 (34.1%) | |
| Other | 11 (6.3%) | 6 (7.1%) | 5 (5.5%) | |
| Endocrine therapy | ||||
| Tamoxifen | 39 (22.3%) | 21 (25%) | 18 (19.8%) | 0.652 |
| Aromatase inhibitor | 45 (25.7%) | 26 (30.9%) | 19 (20.8%) | |
| Other | 10 (5.7%) | 7 (8.3%) | 3 (3.3%) | |
| Trastuzumab | ||||
| Cumulative dose- mg/kg BSA | 105 (97–114) | 105 (97–116) | 105 (97–112) | 0.658 |
| (Median [Q1–Q3]) | ||||
| Type of surgery | ||||
| Mastectomy | 91 (52%) | 38 (45.2%) | 53 (58.2%) | 0.116 |
| Breast conserving surgery | 84 (48%) | 46 (54.8) | 38 (41.8%) |
AC = doxorubicin, cyclophosphamide; BC = breast cancer; BSA = body surface area (The Du Bois formula was used for the calculation); CT = chemotherapy; EC = epirubicin, cyclophosphamide; FAC = 5-FU, doxorubicin, cyclophosphamide; FEC = 5-FU, epirubicin, and cyclophosphamide; Q1–Q3 = quartiles